The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2022
Filed:
Sep. 11, 2015
Applicant:
Novartis Ag, Basel, CH;
Inventors:
David Lebwohl, East Hanover, NJ (US);
Malte Peters, Munich, DE;
Assignee:
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/506 (2006.01); A61K 9/00 (2006.01); C07K 16/30 (2006.01); A61K 31/55 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 9/0053 (2013.01); A61K 31/506 (2013.01); A61K 31/55 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/3023 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/542 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01);
Abstract
Disclosed is a combination comprising an immunomodulator and a second therapeutic agent for use in treating cancer, wherein the immunomodulator is an inhibitor of an immune checkpoint molecule or an activator of a costimulatory molecule, or a combination thereof; and the second therapeutic agent is chosen from one or more of: 1) a c-MET inhibitor; 2) a CDK4/6 inhibitor; 3) a PI3K inhibitor; 4) a BRAF inhibitor; 5) an FGFR inhibitor; 6) a MEK inhibitor, or 7) a BCR-ABL inhibitor. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.